Background: Successful revascularization of chronic total occlusions (CTOs) remains one of the most difficult challenges for interventional cardiologists. However, with the use of drug-eluting stents (DES), long-term outcomes has been improved by reducing recurrence, however, there are limited data regarding outcomes of different DESs following CTO intervention. Methods: A total 201 patients (pts) who underwent percutanous coronary intervention (PCI) with DESs for CTOs lesions were enrolled for this study. We compared the angiographic and clinical outcomes of first generation DES [Paclitaxel-eluting stents (Taxus���) and Sirolimus-eluting stents (Cypher���)] to newer generation DESs [Zotarolimus-eluting stents (Endeavor Resolute���) and Everolimus-eluting stents (Promus Element��� or Xience���). Results: Baseline clinical characteristics were similar between the two groups except that first generations DESs group had a higher percent of smokers (60.9% vs.40%, p=0.023) and dyslipidemia (32% vs.14.3%, p=0.036). At index procedure, first generation DESs showed a trend towards longer lesions length (47.54짹27.3mm vs. 38.62짹24.4, p=0.081), more fluoroscopy time (93.72짹64.3 min vs. 37짹27.91, P<0.001) and higher amount of contrast (430.9짹136.3ml vs. 353.7짹189.3, p=0.027). However, angiographic follow up at six months, there were no significant differences between the two groups. Similar results were found at twelve months clinical follow up (Table). Conclusions: In the current study, there were no significant differences between first and newer generations DESs at 6 months angiographic & 12 months clinical outcomes following successful CTOs intervention.